Tris Pharma acquires Pfizer's NextWave Pharmaceuticals

Sep. 25, 2018 9:39 AM ETPfizer Inc. (PFE)By: Douglas W. House, SA News Editor
  • Privately held Tris Pharma acquires Pfizer (NYSE:PFE +0.5%) subsidiary NextWave Pharmaceuticals for an undisclosed sum. The deal includes two candidates for attention-deficit/hyperactivity disorder (ADHD).
  • Pfizer acquired NextWave in November 2012. ADHD treatment Quillivant XR was approved in the U.S. in September 2012. Earlier this year, the product, along with Quillichew ER, was in short supply due to a manufacturing issue.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.